Jaguar Health, Inc. (JAGX) stock: key figures, P/E, revenue and dividend
Health Care · United States · ISIN US47010C8626
Jaguar Health, Inc. financials
| Fiscal year | 2025 |
|---|---|
| Revenue | 11.51 m USD |
| Gross profit | 7.74 m USD |
| Operating income | -45.91 m USD |
| EBIT | -54.07 m USD |
| Net income | -53.58 m USD |
| Diluted EPS – continuing operations | -22.97 USD |
Full history since 2013, charts and your own formulas
This page shows the last two fiscal years. After free sign-up you get the full income statement, balance sheet and cash flow, price and dividend charts, your own formula metrics and a stock screener covering more than 8,000 companies.
About Jaguar Health, Inc.
Jaguar Health, Inc., a commercial-stage pharmaceuticals company, focuses on developing plant-based prescription medicines for people and animals with gastrointestinal distress. It operates through two segments, Animal Health and Human Health. The company focuses on developing and commercializing prescription and non-prescription products for companion and production animals; and human products. Its lead prescription drug is Mytesi, an anti-secretory antidiarrheal drug for the symptomatic relief of non-infectious diarrhea in adults with HIV/AIDS on antiretroviral therapy; and Canalevia-CA1, a prescription drug product for chemotherapy-induced diarrhea in dogs. It is also developing Crofelemer, an anti-secretory antidiarrheal drug, which is in Phase III clinical trial for prophylaxis of diarrhea in adult cancer patients; Phase II clinical trials for rare/orphan disease indications, including short bowel syndrome with intestinal failure and microvillus inclusion disease; diarrhea-predominant irritable bowel syndrome; and for idiopathic/functional diarrhea. In addition, the company is developing Mytesi which is in Phase III clinical trial for cancer therapy-related diarrhea, as well as Phase II clinical trial for irritable bowel syndrome; and NP-300, a second-generation antidiarrheal drug that is in Phase I clinical trial for symptomatic relief and treatment of moderate-to-severe diarrhea. The company is headquartered in San Francisco, California.
More stocks
- Greenwave Technology Solutions, Inc. (GWAV)
- Global Interactive Technologies, Inc. (GITS)
- MOVING iMAGE TECHNOLOGIES INC. (MITQ)
- SideChannel, Inc. (SDCH)
- XWELL, Inc. (XWEL)
- Cardio Diagnostics Holdings, Inc. (CDIO)
- HAMMER TECHNOLOGY HOLDINGS CORP. (HMMR)
- Sonoma Pharmaceuticals, Inc. (SNOA)
- QHSLab, Inc. (USAQ)
- KIORA PHARMACEUTICALS INC (KPRX)
- Planet Green Holdings Corp. (PLAG)
- SILVERTON ENERGY, INC. (SLTN)
Not investment advice. All data without warranty, price as of 12.11.2026. Details in the risk notice.